Table 2.
Patient characteristics, indication for testicular tissue cryopreservation (TTC), treatment received before TTC, amount of retrieved tissue, and clinical complications. CED exposure was based on the cyclophosphamide equivalent dose calculator (11).
| Patient characteristic | Indication to fertility preservation | Treatment received before testicular tissue cryopreservation | Testicular tissue cryopreservation | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis |
Number of patients,
n (%) |
Age (y),
mean (SD, range) |
Prepubertalc
n (%) |
Conditioning for
HSCT, chemotherapy alone, n (%) |
Conditioning for
HSCT, chemotherapy and radiotherapy, n (%) |
High dose
chemotherapy, n (%) |
Local
radiotherapy, n (%) |
Expected
CED exposure (mg/m2), mean (SD, range) |
Previous exposure
to chemotherapy, n (%) |
Previous exposure
to alkylating chemotherapy, n (%) |
Previous exposure
to radiotherapy, n (%) |
Previous CED
exposure (mg/m2), mean (SD, range) |
Number of
testicular tissue fragments, median (SD) |
Volume of
testicular tissue biopsy (mm3) , median (range) |
Number of
spermatogonia/ cross section, median (range) |
Clinical
complications |
| Malignancies | 31 (88.6) | 8.6 (5.3, 0.5–18.5) | 21 (67.7) | 14 (45.2) | 7 (22.6) | 9 (29) | 1 (3.2) | 13,002 (11,756, 100–61,200) | 19 (61.3) | 16 (51.6) | 2 (6.5)b | 5,466 (3,362, 2,000–15,576) | 27 (12–60) | 54 (24–120) | 2 (0–6) | 1 minor hematoma |
| Hematological malignancies | 15 (42.9) | 10.4 (5.6, 0.7–18.5) | 8 (53.3) | 8 (53.3) | 7 (46.7) | 0 | 0 | 8,365 (5,403, 100–18,388) | 13 (86.7) | 11 (73.3) | 0 (0) | 4,342 (1,394, 2,000–7,400) | 39 (16–60) | 78 (32–120) | 1 (0–6) | 1 minor hematoma |
| Solid Tumors | 16 (45.7) | 6.8 (4.5, 0.5–14.7) | 13 (81.3) | 6 (37.5) | 0 | 9 (56.3) | 1 (6.3) | 16,212 (14,322, 8,892–61,200) | 6 (37.5) | 5 (31.3) | 2 (12.5)b | 7,940 (4,906, 3,125–15,576) | 26 (12–55) | 52 (24–110) | 2.5 (0–5) | 0 |
| Benign conditionsa | 4 (11.4) | 7.9 (2.9, 5.5–12) | 3 (75) | 4 (100) | 0 | 0 | 0 (0) | 1,1012 (5,446, 9,388–12,000) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 31 (19–40) | 62 (38–80) | 2.5 (1–3.5) | 1 minor wound dehiscence |
| Total | 35 (100) | 8.5 (5.1, 0.5–18.5) | 24 (68.6) | 18 (51.4) | 7 (20) | 9 (25.7) | 1 (2.9) | 12,696 (11,059, 100–61,200) | 19 (54.3) | 16 (45.7) | 2 (5.7) | 5,466 (3,362, 2,000–15,576) | 29 (12–60) | 57 (24–120) | 2 (0–6) | 2 |
a
Sickle cell disease and thalassemia.
b
Cranio-spinal irradiation (medulloblastoma).
c
Tanner 1.
HSCT, hematopoietic stem cell transplantation.
CED, Cyclophosphamide equivalent dose.